ES2075331T3 - Inhibicion de la atrofia y de la degradacion proteica muscular en los mamiferos mediante tetraciclinas. - Google Patents

Inhibicion de la atrofia y de la degradacion proteica muscular en los mamiferos mediante tetraciclinas.

Info

Publication number
ES2075331T3
ES2075331T3 ES91201657T ES91201657T ES2075331T3 ES 2075331 T3 ES2075331 T3 ES 2075331T3 ES 91201657 T ES91201657 T ES 91201657T ES 91201657 T ES91201657 T ES 91201657T ES 2075331 T3 ES2075331 T3 ES 2075331T3
Authority
ES
Spain
Prior art keywords
protein degradation
mammals
tetraciclines
atrophy
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91201657T
Other languages
English (en)
Inventor
Bruce Schneider
Robert A Greenwald
Jonathan Maimon
Kenneth Gorray
Lorne M Golub
Thomas F Mcnamara
Nangavarum S Ramamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Application granted granted Critical
Publication of ES2075331T3 publication Critical patent/ES2075331T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ES UN METODO PARA LA INHIBICION DE LA PERDIDA Y DEGRADACION DE LAS PROTEINAS DEL MUSCULO DE MAMIFEROS MEDIANTE LA ADMINISTRACION DE TETRACICLINAS QUE PRODUCE UNA SIGNIFICANTE REDUCCION EN LA PERDIDA Y DEGRADACION DE LAS PROTEINAS DEL MUSCULO. ADEMAS, TAMBIEN SE DESCRIBE UN METODO PARA INCREMENTAR EL CONTENIDO PROTEINICO DEL SISTEMA DEL ESQUELETO MUSCULAR DE LOS MAMIFEROS MEDIANTE LA ADMINISTRACION DE TETRACICLINAS. LAS TETRACICLINAS UTILIZADAS EN LOS METODOS DESCRITOS SON ANTIMICROBIANAS Y NO-ANTIMICROBIANAS. EN OTRO EXPERIMENTO EL METODO Y EL TRATAMIENTO UTILIZO UNA TETRACILICLINA NO-ANTIMICROBIANA, COMO LA DIMTILAMINOTETRACICLINA (CMT).
ES91201657T 1990-06-28 1991-06-27 Inhibicion de la atrofia y de la degradacion proteica muscular en los mamiferos mediante tetraciclinas. Expired - Lifetime ES2075331T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/545,395 US5045538A (en) 1990-06-28 1990-06-28 Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines

Publications (1)

Publication Number Publication Date
ES2075331T3 true ES2075331T3 (es) 1995-10-01

Family

ID=24176048

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91201657T Expired - Lifetime ES2075331T3 (es) 1990-06-28 1991-06-27 Inhibicion de la atrofia y de la degradacion proteica muscular en los mamiferos mediante tetraciclinas.

Country Status (9)

Country Link
US (1) US5045538A (es)
EP (1) EP0464932B1 (es)
JP (1) JP3148284B2 (es)
AT (1) ATE121938T1 (es)
CA (1) CA2045885C (es)
DE (1) DE69109376T2 (es)
DK (1) DK0464932T3 (es)
ES (1) ES2075331T3 (es)
IE (1) IE67541B1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5770588A (en) * 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
DE69304292T2 (de) * 1992-11-17 1997-01-02 Univ New York Tetracycline inclusive nicht antimicrobiel wirksame, chemisch modifizierte Tetracycline hemmende exzessive Kollagenquervernetzung bei Diabetes
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US6043231A (en) * 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5773430A (en) * 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
DK1041991T3 (da) * 1997-12-19 2008-07-28 Univ New York Ikke-antibakterielle tetracycliner til behandling af multipel sklerose
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
ATE336238T1 (de) * 1998-11-18 2006-09-15 Collagenex Pharm Inc Neue 4-dedimethylaminotetracyclinderivate
US6506740B1 (en) 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6946453B2 (en) 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
AU2002256092C1 (en) * 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
CA2462572C (en) * 2001-10-05 2008-11-18 Tetragenex Pharmaceuticals, Inc. Tetracycline derivatives and methods of use thereof
WO2003053447A1 (en) * 2001-12-20 2003-07-03 Hanauske-Abel Hartmut M Treatment for averting or delaying premature delivery
ATE489081T1 (de) 2002-03-29 2010-12-15 Univ New York State Res Found Verwendung von nichtantibakteriellen tetrazyklin- analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
CA2894736C (en) 2003-04-07 2019-07-16 Supernus Pharmaceuticals, Inc. Once daily formulations of tetracyclines
US8999289B2 (en) * 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
JP5409015B2 (ja) 2006-02-14 2014-02-05 プレジデント アンド フェロウズ オブ ハーバード カレッジ ヒストンデアセチラーゼ阻害剤
US8222423B2 (en) * 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
AU2007248656B2 (en) * 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
US8440716B2 (en) * 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US10905704B2 (en) 2015-09-08 2021-02-02 Ecole Polytechnique Federale De Lausanne (Epfl) Agents and methods using thereof for the prevention and treatment of stem cell muscle disorders
WO2017042196A2 (en) * 2015-09-08 2017-03-16 Ecole Polytechnique Federale De Lausanne (Epfl) Agents and methods using thereof for the prevention and treatment of stem cells senescence

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666897A (en) * 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4935412A (en) * 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same

Also Published As

Publication number Publication date
US5045538A (en) 1991-09-03
DK0464932T3 (da) 1995-07-17
IE912242A1 (en) 1992-01-01
DE69109376T2 (de) 1995-09-07
JP3148284B2 (ja) 2001-03-19
EP0464932A2 (en) 1992-01-08
DE69109376D1 (de) 1995-06-08
EP0464932A3 (en) 1992-04-01
EP0464932B1 (en) 1995-05-03
CA2045885A1 (en) 1991-12-29
CA2045885C (en) 2003-05-13
JPH04230323A (ja) 1992-08-19
IE67541B1 (en) 1996-04-17
ATE121938T1 (de) 1995-05-15

Similar Documents

Publication Publication Date Title
EP0464932A3 (en) Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
EG19814A (en) A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
ES2083030T3 (es) Metodo de tratamiento de la inflamacion ocular.
ES2135083T3 (es) Trifeniletilenos para la prevencion y el tratamiento de la osteoporosis.
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
EP0313305A3 (en) Photoprotection compositions comprising chelating agents
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
BG100960A (bg) Дозирани форми с контролирано освобождаване на азитромицин
ATE150646T1 (de) Behandlung von peridontalkrankheiten mit alendronat
MY109928A (en) Fatty acid treatment
BR9503406A (pt) Formulaçoes farmacêuticas adaptadas para inhibir para perda de osso em um ser humano
CA2002859A1 (en) Method of treating epithelial disorders
WO1990014067A3 (en) Methods for treating anxiety with sigma receptor ligands
AU609664B1 (en) A method of treating premature ejaculation using sertraline
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
WO1993003714A3 (en) Method for treatment of metabolic disorders
ZA926837B (en) A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
RU93058532A (ru) Фармацевтическая композиция для остеоиндукции, способ генерации новой кости
SE9601395D0 (sv) New therapeutic treatment 1
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
EP0744176A3 (en) Methods for inhibiting bone loss
EP0451869A3 (en) Use of steroid derivatives in the treatment of endometriosis
DE69626916D1 (de) Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 464932

Country of ref document: ES